FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058164070> ?p ?o ?g. }

• W2058164070 endingPage "333" @default.
• W2058164070 startingPage "326" @default.
• W2058164070 abstract "The roots of Mirabilis himalaica have been used in Tibetan folk medicine for treatment of uterine cancer, nephritis edematous, renal calculus and arthrodynia. In our previous work, the ethanol extract of roots had shown potent cytotoxicity against human cancer cells. However, no information is available on the antitumor effect of Mirabilis himalaica. The aim of the present study was to investigate the active constituents guided by bioassay and evaluate the related antitumor efficacy in vitro and in vivo. The active subextract (ethyl acetate) was subjected to successive chemical separation using a combination of silica gel, LH-20 chromatography and semi-preparative HPLC. The structures were determined by spectroscopic analysis techniques such as nuclear magnetic resonance (NMR) and mass spectrometry. Three human cancer cell lines, A549, HepG2 and HeLa were used for in vitro cytotoxicity evaluation of all isolated compounds by MTT-assay. Then, the potent and novel compound mirabijalone E was employed to the mechanism study againstA549 cells. BrdU immunofluorescence, soft agar assay and cell cycle analysis were employed to detect the cell proliferation effects. Annexin V-FITC/PI staining assay was used for examining apoptotic effects. Expression levels of apoptosis-related proteins were determined by western blot assay. in vivo tumorigenic assay was used to evaluate the xenograft tumor growth treated with mirabijalone E. One new rotenoid compound, mirabijalone E, together with eight known rotenoids was isolated from Mirabilis himalaica. Mirabijalone E, 9-O-methyl-inone B, boeravinone C and boeravinone H exhibited cytotoxicity against A 549 and HeLa cells. Further study on mirabijalone E was carried out in vitro and in vivo. Mirabijalone E inhibited A549 cells growth in a time and dose-dependent manner, which arrested cell cycle in S phase. Mechanistically, mirabijalone E treatment resulted in the increase of Bax expression level, the decrease of Bcl-2 level and the activation of caspase-3, which suggested the activation of apoptosis cascades. Consequently, the xenograft treated with mirabijalone E showed markedly suppressed tumor growth. The result suggested that mirabijalone E, together with active compounds, 9-O-methyl-4-hydroxyboeravinone B, boeravinone C and boeravinone H could be a promising candidate for cancer therapy." @default.
• W2058164070 created "2016-06-24" @default.
• W2058164070 creator A5000584148 @default.
• W2058164070 creator A5004395331 @default.
• W2058164070 creator A5018314790 @default.
• W2058164070 creator A5021333738 @default.
• W2058164070 creator A5052735511 @default.
• W2058164070 creator A5053256487 @default.
• W2058164070 creator A5056213564 @default.
• W2058164070 creator A5057478907 @default.
• W2058164070 date "2014-08-01" @default.
• W2058164070 modified "2023-09-26" @default.
• W2058164070 title "Mirabijalone E: A novel rotenoid from Mirabilis himalaica inhibited A549 cell growth in vitro and in vivo" @default.
• W2058164070 cites W1967812699 @default.
• W2058164070 cites W1969815623 @default.
• W2058164070 cites W1980854786 @default.
• W2058164070 cites W1981948280 @default.
• W2058164070 cites W1984721750 @default.
• W2058164070 cites W1995485603 @default.
• W2058164070 cites W2000610781 @default.
• W2058164070 cites W2002788713 @default.
• W2058164070 cites W2010376765 @default.
• W2058164070 cites W2017290556 @default.
• W2058164070 cites W2022089184 @default.
• W2058164070 cites W2025336062 @default.
• W2058164070 cites W2069547847 @default.
• W2058164070 cites W2074672504 @default.
• W2058164070 cites W2080122317 @default.
• W2058164070 cites W2100101437 @default.
• W2058164070 cites W2142959934 @default.
• W2058164070 cites W2155127143 @default.
• W2058164070 doi "https://doi.org/10.1016/j.jep.2014.05.034" @default.
• W2058164070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24882730" @default.
• W2058164070 hasPublicationYear "2014" @default.
• W2058164070 type Work @default.
• W2058164070 sameAs 2058164070 @default.
• W2058164070 citedByCount "25" @default.
• W2058164070 countsByYear W20581640702015 @default.
• W2058164070 countsByYear W20581640702016 @default.
• W2058164070 countsByYear W20581640702017 @default.
• W2058164070 countsByYear W20581640702018 @default.
• W2058164070 countsByYear W20581640702019 @default.
• W2058164070 countsByYear W20581640702020 @default.
• W2058164070 countsByYear W20581640702021 @default.
• W2058164070 countsByYear W20581640702022 @default.
• W2058164070 countsByYear W20581640702023 @default.
• W2058164070 crossrefType "journal-article" @default.
• W2058164070 hasAuthorship W2058164070A5000584148 @default.
• W2058164070 hasAuthorship W2058164070A5004395331 @default.
• W2058164070 hasAuthorship W2058164070A5018314790 @default.
• W2058164070 hasAuthorship W2058164070A5021333738 @default.
• W2058164070 hasAuthorship W2058164070A5052735511 @default.
• W2058164070 hasAuthorship W2058164070A5053256487 @default.
• W2058164070 hasAuthorship W2058164070A5056213564 @default.
• W2058164070 hasAuthorship W2058164070A5057478907 @default.
• W2058164070 hasConcept C109316439 @default.
• W2058164070 hasConcept C150903083 @default.
• W2058164070 hasConcept C153911025 @default.
• W2058164070 hasConcept C185592680 @default.
• W2058164070 hasConcept C190283241 @default.
• W2058164070 hasConcept C202751555 @default.
• W2058164070 hasConcept C207001950 @default.
• W2058164070 hasConcept C2777366897 @default.
• W2058164070 hasConcept C2780783641 @default.
• W2058164070 hasConcept C54355233 @default.
• W2058164070 hasConcept C55493867 @default.
• W2058164070 hasConcept C62112901 @default.
• W2058164070 hasConcept C81885089 @default.
• W2058164070 hasConcept C86803240 @default.
• W2058164070 hasConcept C98274493 @default.
• W2058164070 hasConceptScore W2058164070C109316439 @default.
• W2058164070 hasConceptScore W2058164070C150903083 @default.
• W2058164070 hasConceptScore W2058164070C153911025 @default.
• W2058164070 hasConceptScore W2058164070C185592680 @default.
• W2058164070 hasConceptScore W2058164070C190283241 @default.
• W2058164070 hasConceptScore W2058164070C202751555 @default.
• W2058164070 hasConceptScore W2058164070C207001950 @default.
• W2058164070 hasConceptScore W2058164070C2777366897 @default.
• W2058164070 hasConceptScore W2058164070C2780783641 @default.
• W2058164070 hasConceptScore W2058164070C54355233 @default.
• W2058164070 hasConceptScore W2058164070C55493867 @default.
• W2058164070 hasConceptScore W2058164070C62112901 @default.
• W2058164070 hasConceptScore W2058164070C81885089 @default.
• W2058164070 hasConceptScore W2058164070C86803240 @default.
• W2058164070 hasConceptScore W2058164070C98274493 @default.
• W2058164070 hasFunder F4320321001 @default.
• W2058164070 hasIssue "1" @default.
• W2058164070 hasLocation W20581640701 @default.
• W2058164070 hasLocation W20581640702 @default.
• W2058164070 hasOpenAccess W2058164070 @default.
• W2058164070 hasPrimaryLocation W20581640701 @default.
• W2058164070 hasRelatedWork W1601301841 @default.
• W2058164070 hasRelatedWork W2100017209 @default.
• W2058164070 hasRelatedWork W2120903031 @default.
• W2058164070 hasRelatedWork W2350027679 @default.
• W2058164070 hasRelatedWork W2366463941 @default.
• W2058164070 hasRelatedWork W2383563819 @default.
• W2058164070 hasRelatedWork W2464301138 @default.

• next